The European Thyroid Association (ETA) has classified posttreatment cervical ultrasound findings in thyroid cancer patients based on their association with disease persistence/recurrence.
D
iagnoses of differentiated thyroid cancer (DTC) have increased nearly 3-fold since 1975 (1) . Most cases involve papillary thyroid cancers (PTC) with indolent behaviors. However, locoregional disease is found in 7%-28% of PTC patients during follow-up, depending on the baseline risk class and response to initial therapy (2) (3) (4) (5) .
Almost all of this disease is discovered with cervical ultrasonography (US), the most sensitive tool for exploring the thyroid bed and cervical lymph node compartments (6) and the internationally acknowledged cornerstone of the postoperative surveillance program (5, 7) .
Debate continues, however, on the management of sonographically detected abnormalities, in particular when these lesions should be subjected to fine-needle aspiration biopsy (FNAB). Confirmation of locoregional metastatic involvement often leads to further treatment, but if this course of action has already been excluded by an analysis of costs and benefits, FNAB serves little purpose and can even be an unnecessary source of stress for the patient. According to the American Thyroid Association (ATA) practice guidelines, surgery is the preferred treatment for locoregional disease (5) , and in expert hands, neck dissections are acceptably safe procedures. But they are by no means risk free, particularly when they involve areas already subjected to surgery (8 -10) . Moreover, not all dissections are carried out by experts, and even those that are can be associated with considerable morbidity. These considerations become increasingly important in light of the efficacy rates of these procedures, as low as 40%-50% in some series (11) (12) (13) , and the fact that in up to 9% of cases the resected tissues prove to be benign (11, 13, 14) . Even when neck lesions are cytologically confirmed to be malignant, their progression is usually extremely slow (15, 16) and their impact on clinical outcomes far from clear (17) (18) (19) (20) (21) (22) .
Support is thus growing for the use of more cautious, conservative strategies for managing sonographically detected neck lesions in DTC patients. The 2015 ATA Guidelines allow for active surveillance of suspicious, nonthreatening lymph nodes whose smallest diameters are less than 8 -10 mm. Biopsy should be reserved for lesions that exceed this limit and/or display active growth, and it should be used only when management of the case is likely to be modified if positive findings emerge (5) . Specific recommendations are lacking, however, on the management of small masses detected in the postoperative thyroid bed. Although some of these lesions are indeed malignant, many prove to be foci of postoperative fibrosis or suture granulomas.
In this scenario, the sonographic features of neck lesions acquire increasing importance in decisions regarding the posttreatment management of DTC. Several authors have described the sonographic characteristics of abnormal lymph nodes and thyroid bed nodules (23) (24) (25) (26) . Some features are highly specific in identifying persistence/recurrence; others are sensitive markers of disease but low on specificity (23) . To aid clinicians in exploiting the diagnostic value of these markers, the European Thyroid Association (ETA) has published a set of criteria for estimating the malignancy risk of sonographically identified neck masses and lymph nodes based on the assessment of a series of US characteristics classified as normal, indeterminate, and suspicious (27) . This study was conducted to assess the value of this classification in clinical decision making regarding the use or deferral of FNAB. Our primary objective was to determine how well this classification predicts the evolution of sonographically detected neck lesions, in terms of persistence and/or growth, during the posttreatment surveillance of DTC patients. As secondary end points, we also assessed rates of complications and the occurrence of new lesions.
Materials and Methods

Study design
We conducted a retrospective observational study in the thyroid cancer follow-up center of a large teaching hospital in Italy. The study protocol was approved by the institutional review board. Written informed consent was obtained from all patients whose data were analyzed.
The center's DTC follow-up protocol
Patients with DTC are initially seen 6 -12 months after primary treatment and at least once a year thereafter. Each visit includes serum thyroglobulin (Tg) assays (DYNO test Tg-plus, Brahms Diagnostics GmbH; functional sensitivity 0.2 ng/mL), radioimmunometric assays of circulating Tg antibodies (Architect System Anti-Tg; Abbott Laboratories; functional sensitivity 0.31 IU/mL), and high-resolution gray-scale and color Doppler US of the thyroid bed and cervical lymph node compartments. The US examinations are performed by an endocrinologist with specific training and expertise in sonographic examination of the neck. The characteristics of the examiner and the standard examination protocol are both in conformity with ETA recommendations (27) . Additional imaging studies and/or FNAB for cytology are ordered at the examiner's discretion in accordance with evidence-based guidelines (5, 28) .
Study cohort selection and division into subgroups
We reviewed the center's case database and identified patients diagnosed with DTC and referred for follow-up between January 1, 2005, and December 31, 2014. Those who met the following criteria were included in the study cohort: 1) surgical pathology report confirming diagnosis of DTC (ie, papillary, follicular, or poorly differentiated thyroid cancer); 2) primary treatment consisting of total or near-total thyroidectomy, with or without central and/or lateral neck dissection and radioiodine remnant ablation (RRA); 3) abnormal findings on at least two consecutive neck sonograms performed in our center; and 4) subsequent follow-up consisting solely of active surveillance.
Static images from the baseline US examination (ie, the first showing abnormalities) were reexamined by an independent reviewer. Each thyroid bed or lymph node lesion was recorded and classified in accordance with the schema shown in Table 1 . The lesion features considered were those that were routinely eval- press.endocrine.org/journal/jcem 3037 uated by our staff during the study period. Each was retrospectively designated suspicious or indeterminate in accordance with the ETA guidelines (27) . When the reviewer's and original examiner's judgments were discordant, both operators reexamined the images and reached a consensus judgment. The cohort itself was then divided into two groups: group S comprising patients with at least one lesion classified as suspicious and group I comprising those whose lesions were all considered indeterminate. Medical records were reviewed and demographic and clinical characteristics recorded for each patient at the time of thyroid cancer diagnosis, at study baseline, and at all subsequent visits through June 30, 2015 (data lock).
Analysis of follow-up data
Clinical findings, US images and reports, and laboratory data relative to each postbaseline follow-up visit were reviewed. We recorded the results of serum Tg, Tg antibodies, and TSH assays as well as the location, dimensions, and sonographic features of each lesion observed (including those appearing after baseline, provided they were observed on at least two consecutive scans). The primary end points were growth of one or more lesions at any time during follow-up and persistence of one or more neck lesions at the end of follow-up. Growth was defined as an increase of greater than 3 mm in the largest diameter relative to that observed at initial detection. Persistent lesions were those still visualized sonographically at the final visit (ie, the most recent visit for patients who were still undergoing active surveillance at data lock or the last visit in our center before the patient was referred for treatment, died or was lost to follow-up). We also recorded the number of lesions that were detected after baseline (provided they were seen on at least two consecutive scans) and the number of patients who had clinical evidence of complications related to lesion growth (dyspnea, dysphagia, bleeding, skin ulceration).
Statistical analysis
Differences between categorical variables (expressed as numbers and percentages) were evaluated with the 2 test or the Fischer exact test for small samples; differences between continuous variables (reported as medians and ranges) were assessed with the Mann-Whitney test. Values of P Ͻ .05 were considered statistically significant. StatView 5.0.1 software (SAS Institute, Inc) was used for statistical analyses.
Results
Cohort profile at baseline
Six hundred thirty-seven patients with pathologically confirmed DTC were referred to our follow-up center between January 31, 2005, and December 31, 2014 (Supplemental Figure 1) . In 117 cases (18%), neck US performed by our staff had revealed one or more abnormalities. In 18 of these cases, subsequent US findings were unavailable (contact interrupted because the patient was referred directly for treatment or lost to follow-up shortly after lesion detection or because the next visit was scheduled after data lock). In 41 others, none of the lesions observed at baseline were seen on the subsequent US scan. The remaining 58 DTC patients constituted the study cohort: they had a total of 94 neck lesions, each visualized on at least two consecutive scans. In all 58 cases, treatment and/or FNAB were deferred (based on decisions made jointly by patients and physicians) and the patients placed under active surveillance.
Their characteristics are summarized in Table 2 . All 58 had PTC. The median age at diagnosis was 46 years, almost two-thirds were women, and in 71% of the cases, the ATA risk level was intermediate or high. All had initially been treated with total thyroidectomy; 25 (43%) had also undergone some form of neck dissection (central in 13, lateral in two, both in 10), and over 80% had had RRA. Postoperatively, all received levothyroxine at doses that kept serum TSH levels in the low to normal range. At baseline (ie, at study entry), 10 of the 58 patients (17%) had already undergone revision neck dissections and were being followed up for second neck recurrences. Nine (16%) had distant metastases.
At baseline, 33 of the 58 patients (57%) had one or more suspicious lesions and were therefore assigned to group S. Their profile at the time of initial treatment resembled that of the 25 patients whose neck lesions were all classified as indeterminate (43%) (group I). Group S patients had significantly larger primary tumors, their initial treatment was more likely to include RRA, and they had a higher rate of postoperative whole-body scan showing neck uptake outside the thyroid bed. There were no significant differences in American Joint Committee on Cancer (AJCC) stages or the initial ATA risk classification. At study entry, however, the differences between the two groups were more marked, involving disease stage, presence of distant metastases, and a history of revision surgery (Table 2) . Table 3 summarizes the characteristics of the 94 neck lesions visualized by our staff at baseline, which included 16 thyroid bed masses and 78 lymph nodes. The 49 suspicious lesions (52%) were significantly larger than those classified as indeterminate. Ten thyroid bed lesions (63%)
were hypoechoic nodules with no other abnormal features. Almost all the 78 abnormal lymph nodes were round with no detectable hilum; 43 also presented one or more suspicious features (the most common combination being solid aspect with cystic areas and microcalcifications). 
Follow-up
Ten patients (17%) (7 from group S) developed one or more new neck lesions after baseline. The 19 new lesions were almost all lymph nodes (n ϭ 17: six in level IV, five in level III, four in level VI, and one each in levels II and VII), and 10 (53%) (all observed in group S patients) were considered suspicious. The total number of lesions followed up in the study was thus 113 (Figure 1) . At first appearance, greater than half the 95 lymph node lesions were classified as suspicious, whereas most of the 18 thyroid bed lesions were considered indeterminate. Only two thyroid bed lesions displayed growth during follow-up, but all 18 were still visualized at the final visit (median 3.7 y after baseline US, range 0.2-10.5). Growth was slightly more common in lymph node lesions, regardless of whether they were indeterminate or suspicious. At the final visit, however, 17 of the abnormal lymph nodes had disappeared, including one indeterminate lesion that had formerly displayed growth. Lesion resolution was significantly more common among indeterminate nodal lesions (P Ͻ .001 vs those considered suspicious). The two suspicious nodes that disappeared had both been detected in the same patient and were both characterized by undetectable hila and peripheral vascularization. Figure 2 shows patient-level outcomes recorded in groups I and S. Growth of one or more lesions during follow-up was significantly more common in group S (36% vs 8%, P ϭ .01). In both groups, however, most patients experienced no structural progression, and none developed complications related to lesion growth. The final neck US findings were completely negative in nine of the 25 patients in group I (36%). This finding was significantly less common in group S (5%, P ϭ .014 vs group I). The median time to normalization (from baseline to first negative US) in these cases was 2.9 years (0.9 -4.0 y), and the median duration of the postnormalization follow-up was 0.5 years (range 0 -4.1 y).
As shown in Table 4 , in all of the patients whose lesions ultimately disappeared, the basal serum Tg levels measured at the time of the last US examination were undetectable (ie, Ͻ0.2 ng/mL) or indeterminate (ie, Յ1 ng/mL with no evidence of Tg antibodies or with declining Tg antibodies). The nine patients with evidence of distant metastases (all in group S) were the same ones with distant metastases at baseline. Based on the data shown in the table, the clinical judgment of the medical staff, and the preferences of the patients, 8 of the 32 group S patients with persistent neck lesions were referred for treatment, and five others (three from group S, two from group I) underwent FNAB for cytological assessment. In all 13 cases, pathology findings confirmed the presence of recurrent neck disease.
Discussion
We retrospectively analyzed the sonographic features of neck lesions detected in 58 PTC patients treated with neartotal thyroidectomy, with or without RRA, to determine whether they could provide guidance for surveillance management decisions in the absence of FNAB. Using the ETA's recently published classification of cervical US findings, we divided our patient cohort into two subgroups: those with at least one lesion classified as suspicious (group S) and those whose abnormalities all fell within the indeterminate category (group I) (27) . All of the patients were managed with active surveillance based mainly on serial US studies and serum Tg assays.
In the cohort as a whole, structural progression rates during follow-up (median 3.7 y) were low: fewer than 20% of the patients developed new neck lesions, only 24% experienced lesion growth, and none experienced lesion-related complications. Most important, at the final follow-up visit, 17% of the patients had no abnormalities whatsoever on Table 1 . Like the lesions present at baseline, new lesions that developed during follow-up were considered only when visualized on two or more consecutive ultrasound scans. Growth was defined as an increase in largest diameter of greater than 3 mm compared with that at initial detection. LNL, lymph node lesions; TBL, thyroid bed lesions. doi: 10.1210/jc.2016-1440 press.endocrine.org/journal/jcem 3041 the US examination. However, the two subgroups were characterized by significantly different disease behaviors and outcomes. In group I, lesion growth was observed in only 8% of the patients, and in 36% all lesions resolved spontaneously over time. Lesion growth and persistence were both much more common when one or more of the patient's lesions presented suspicious features: in 36% of the group S patients, at least one lesion increased in size during follow-up, and in 97%, abnormalities were still detectable at the final visit. These findings suggest that, in the presence of sonographically detected neck lesions, the fact that the abnormalities are all indeterminate rather than frankly suspicious adds support to a decision to defer FNAB and/or additional treatment. This is important because abnormal neck US findings are common during the follow-up of DTC patients, particularly those with PTCs. Our cohort was selected from a background population of more than 600 consecutive DTC patients followed up in our center since 2005 with one or more neck US examinations per year. As shown in Supplemental Figure 1 , almost 20% of these individuals had at least one scan showing abnormalities, but the percentage decreased by approximately half when we considered only those whose lesions were still present at the next visit. Ninety-five percent of the lesions that disappeared between the first and second scans were cervical lymph nodes, and 83% of these displayed only indeterminate features. The same pattern emerged in the study cohort itself (Figure 1 ). Resolution appears to be much less common among thyroid bed nodules, which often represent foci of postoperative fibrosis or suture granulomas (15, 29, 30) .
Disappearance of nodes with suspicious features has been reported (16) . In our cohort, only two suspicious nodes, both documented in the same patient on two consecutive scans, resolved completely. The lesions were located ipsilaterally to the primary tumor (one in level IV, the other in level VI), and both had presented with absent hila and evidence of peripheral vascularization. Although the latter feature is regarded as a sensitive and also relatively specific predictor of malignancy, it is also observed in up to 18% of reactive nodes (23) . Size increases are also compatible with reactive phenomena, and this is a plausible explanation for the single lesion in group I that disappeared after exhibiting growth of 7 mm.
It is important to note that the US-based risk class defined at the first sign of neck lesions may require periodic revision owing to the appearance of new abnormalities and/or changes in the appearance of those originally present. Neither of these situations occurred within our study. As for the 19 new lesions, only 10 were classified as suspicious, and all 10 developed in patients already assigned to group S. Aside from size changes, the sonographic characteristics of the baseline lesions in our cohort did not vary appreciably during follow-up. As expected, the US-based risk classification showed concordance with other clinical predictors of recurrent thyroid cancer. For example, group S patients also tended to have higher-stage tumors and were more likely to have undergone revision neck surgery for persistent/recurrent PTC prior to study entry (Table 2) ; they also had higher Tg levels at the final assessment. Previous studies (15, 16) have already shown that neck lesions detected sonographically during the postoperative follow-up of DTC patients frequently follow an indolent course and that noninvasive surveillance is usually a safe, cost-effective strategy for managing cases of this type. The outcomes observed in our study suggest that postponing invasive procedures such as FNA or further treatments is a safe course of action, even in population with higher-risk profiles, particularly when the neck lesions are characterized by exclusively indeterminate features.
The main limits of this study were the retrospective nature of our analyses and the small size of the study cohort. It is also important to stress that the present study was conducted in a single center, and all the US examinations were performed by a single physician with extensive training and experience. These factors may well have enhanced the uniformity of the examinations themselves and the descriptions of findings. However, they might also reduce the applicability of our study findings to other settings. The main shortcoming of cervical US is its operator dependence. The impact of this problem can be attenuated to some extent by the use of standardized examination and reporting protocols, such as those proposed by the ETA (27) . Greater uniformity would not only improve communication between clinicians, but also it would also facilitate comparison of the findings from different studies, an essential step for identifying high-quality, cost-effective management strategies (31).
In conclusion, previous studies (15, 16) have shown that neck lesions detected sonographically during the postoperative follow-up of DTC patients frequently follow an indolent course and that noninvasive surveillance is usually a safe, cost-effective strategy for managing cases of this type. Our study expands these findings. The outcomes we observed suggest that watchful waiting can be a safe course of action, even in population with higher-risk profiles, particularly when the neck lesions are characterized by exclusively indeterminate sonographic features. Risk estimates based on the ETA's evidence-based classification of sonographically detected neck abnormalities can be a useful aid for identifying PTC patients for whom a more relaxed follow-up protocol can be proposed. Invasive procedures and additional imaging studies can then be reserved for cases in which the neck lesions are most likely to pose an actual threat.
